NewDEL Biotech Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A1

  • Investors
  • 9

NewDEL Biotech General Information

Description

Developer of innovative drugs designed for tumors. The company offers DNA Encoded Library technology to significantly improve the success rate of drugs, thereby enabling tumor patients to have next-generation alternative medicines.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Unit 9-5, Building T1, Chuanyiyuan, Number 4 Guanhe Road, Junzibu Community
  • Guanlan Subdistrict, Longhua District
  • Shenzhen, Guangdong 518110
  • China
+86 0755
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Unit 9-5, Building T1, Chuanyiyuan, Number 4 Guanhe Road, Junzibu Community
  • Guanlan Subdistrict, Longhua District
  • Shenzhen, Guangdong 518110
  • China
+86 0755

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NewDEL Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC (Series A1) 21-Jan-2026 Completed Generating Revenue
6. Early Stage VC (Series A1) 12-Mar-2025 Completed Generating Revenue
5. Early Stage VC (Series A) 11-Mar-2024 Completed Generating Revenue
4. Early Stage VC 28-Jul-2023 Completed Generating Revenue
3. Early Stage VC 01-Jun-2022 Completed Generating Revenue
2. Seed Round 17-Jul-2021 Completed Startup
1. Accelerator/Incubator 28-Apr-2021 Completed Startup
To view NewDEL Biotech’s complete valuation and funding history, request access »

NewDEL Biotech Patents

NewDEL Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025040141-A1 Use of compound 1 in treating or preventing disease associated with c-kit mutation or c-kit fusion mutation Inactive 23-Aug-2023
JP-2026527881-A Use of compound 1 in the treatment or prevention of diseases associated with ret fusion and/or ret mutations Pending 01-Jul-2023
EP-4734998-A1 Use of compound 1 in treatment or prevention of disease related to ret fusion and/or ret mutation Pending 01-Jul-2023
EP-4734998-A4 Use of compound 1 in treatment or prevention of disease related to ret fusion and/or ret mutation Pending 01-Jul-2023
WO-2025007816-A1 Use of compound 1 in treatment or prevention of disease related to ret fusion and/or ret mutation Inactive 01-Jul-2023 C07D487/04
To view NewDEL Biotech’s complete patent history, request access »

NewDEL Biotech Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
XtalPi Technology Corporation Minority
Tsingda Venture Capital PE/Buyout Minority
Shenzhen High-Tech Investment Venture Capital Minority
Zhuhai Hecheng Zhiyi Capital Management Growth/Expansion Minority
Bangqin Capital Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

NewDEL Biotech FAQs

  • When was NewDEL Biotech founded?

    NewDEL Biotech was founded in 2021.

  • Where is NewDEL Biotech headquartered?

    NewDEL Biotech is headquartered in Shenzhen, China.

  • What industry is NewDEL Biotech in?

    NewDEL Biotech’s primary industry is Drug Discovery.

  • Is NewDEL Biotech a private or public company?

    NewDEL Biotech is a Private company.

  • What is NewDEL Biotech’s current revenue?

    The current revenue for NewDEL Biotech is .

  • Who are NewDEL Biotech’s investors?

    XtalPi Technology, Tsingda Venture Capital, Shenzhen High-Tech Investment, Zhuhai Hecheng Zhiyi Capital Management, and Bangqin Capital are 5 of 9 investors who have invested in NewDEL Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process